DJIA 18,113.94 -49.05 -0.27%
NASDAQ 5,096.63 -9.96 -0.20%
S&P 500 2,120.29 -3.19 -0.15%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

59.98 -0.59 (-0.97%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $59.98 -0.97%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $60.12
Previous Close $60.57
Daily Range $59.38 - $60.86
52-Week Range $38.49 - $75.17
Market Cap $8.9B
P/E Ratio -242.28
Dividend (Yield) $0.00 (0.0%)
Volume 319,722
Average Daily Volume 1,038,527
Current FY EPS -$0.98

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics

Alkermes Plc's ALKS 3831 could help patients that take atypical antidepressants avoid gaining weight.

The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis a

The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Ye

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog

3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog

Benzinga's Top Initiations

Top Analyst Upgrades and Downgrades: Alibaba, Mobileye, NetApp, Nike, Salesforce.com, Stratasys and

Top Analyst Upgrades and Downgrades: Alibaba, Mobileye, NetApp, Nike, Salesforce.com, Stratasys and More

4 SMID-Cap Biotechs Barclays Just Confessed It Loves

First Week of ALKS July 17th Options Trading

Top Analyst Upgrades and Downgrades: Alkermes, Cisco, Gap, Rackspace, SouFun, Verizon and More

Alkermes' Q1 Loss Narrower than Expected, Maintains View - Analyst Blog

Alkermes (ALKS) Earnings Report: Q1 2015 Conference Call Transcript

See More ALKS News...

ALKS's Top Competitors

ALKS $59.98 (-0.97%)
Current stock: ALKS
AMGN $157.73 (-1.69%)
Current stock: AMGN
GILD $113.01 (0.49%)
Current stock: GILD
BIIB $400.74 (-0.54%)
Current stock: BIIB